State Street SPDR S&P Pharmaceuticals ETF
XPH
69 hedge funds and large institutions have $332M invested in State Street SPDR S&P Pharmaceuticals ETF in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 13 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
16% more capital invested
Capital invested by funds: $287M → $332M (+$45.5M)
6.5% more ownership
Funds ownership: 63.93% → 70.43% (+6.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 72 → 69 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$30.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.6M |
| 3 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
+$4.51M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$1.97M |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFG
Pacific Financial Group
Bellevue,
Washington
|
-$4.99M |
| 2 |
Citigroup
New York
|
-$4.83M |
| 3 |
Morgan Stanley
New York
|
-$4.41M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.87M |
| 5 |
Jane Street
New York
|
-$3.69M |
XPH Hedge Fund Activity: Q2 2014 in Review
69 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2014, worth a combined $332M — up 16% from $287M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of XPH and 10 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 24 added.
The largest buyer was Goldman Sachs, adding an estimated $30.9M. The largest seller was Pacific Financial Group, exiting entirely with an estimated $4.99M sold.
- 69 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2014, down from 72 in Q1 2014.
- Funds reported $332M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2014, up 16% quarter-over-quarter.
- 10 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2014 and 13 closed out, a net change of -3 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2014 was Goldman Sachs, an estimated $30.9M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2014 was Pacific Financial Group, an estimated $4.99M sold.
Based on aggregated 13F filings for Q2 2014.